195 related articles for article (PubMed ID: 14512794)
1. Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2.
Nagayama H; Sato K; Morishita M; Uchimaru K; Oyaizu N; Inazawa T; Yamasaki T; Enomoto M; Nakaoka T; Nakamura T; Maekawa T; Yamamoto A; Shimada S; Saida T; Kawakami Y; Asano S; Tani K; Takahashi TA; Yamashita N
Melanoma Res; 2003 Oct; 13(5):521-30. PubMed ID: 14512794
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
3. 1-alpha,25-Dihydroxyvitamin D3 (1,25(OH)(2)D(3)) hampers the maturation of fully active immature dendritic cells from monocytes.
Canning MO; Grotenhuis K; de Wit H; Ruwhof C; Drexhage HA
Eur J Endocrinol; 2001 Sep; 145(3):351-7. PubMed ID: 11517017
[TBL] [Abstract][Full Text] [Related]
4. Human Chorionic Villous Mesenchymal Stem Cells Modify the Functions of Human Dendritic Cells, and Induce an Anti-Inflammatory Phenotype in CD1+ Dendritic Cells.
Abomaray FM; Al Jumah MA; Kalionis B; AlAskar AS; Al Harthy S; Jawdat D; Al Khaldi A; Alkushi A; Knawy BA; Abumaree MH
Stem Cell Rev Rep; 2015 Jun; 11(3):423-41. PubMed ID: 25287760
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.
Escobar A; López M; Serrano A; Ramirez M; Pérez C; Aguirre A; González R; Alfaro J; Larrondo M; Fodor M; Ferrada C; Salazar-Onfray F
Clin Exp Immunol; 2005 Dec; 142(3):555-68. PubMed ID: 16297169
[TBL] [Abstract][Full Text] [Related]
6. Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate.
Vilella R; Benítez D; Milà J; Lozano M; Vilana R; Pomes J; Tomas X; Costa J; Vilalta A; Malvehy J; Puig S; Mellado B; Martí R; Castel T
Cancer Immunol Immunother; 2004 Jul; 53(7):651-8. PubMed ID: 14999431
[TBL] [Abstract][Full Text] [Related]
7. Characterization of canine monocyte-derived dendritic cells with phenotypic and functional differentiation.
Wang YS; Chi KH; Liao KW; Liu CC; Cheng CL; Lin YC; Cheng CH; Chu RM
Can J Vet Res; 2007 Jul; 71(3):165-74. PubMed ID: 17695590
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100.
Panelli MC; Wunderlich J; Jeffries J; Wang E; Mixon A; Rosenberg SA; Marincola FM
J Immunother; 2000; 23(4):487-98. PubMed ID: 10916759
[TBL] [Abstract][Full Text] [Related]
9. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study.
Oosterwijk-Wakka JC; Tiemessen DM; Bleumer I; de Vries IJ; Jongmans W; Adema GJ; Debruyne FM; de Mulder PH; Oosterwijk E; Mulders PF
J Immunother; 2002; 25(6):500-8. PubMed ID: 12439347
[TBL] [Abstract][Full Text] [Related]
10. Feasibility to generate monocyte-derived dendritic cell from coculture with melanoma tumor cells in the presence of granulocyte/macrophage colony-stimulating factor (GM-CSF) and interleukin-4.
Kim YT; Hersh EM; Trevor KT
Am J Reprod Immunol; 2003 Apr; 49(4):230-8. PubMed ID: 12852497
[TBL] [Abstract][Full Text] [Related]
11. Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial).
Ridolfi L; de Rosa F; Fiammenghi L; Petrini M; Granato AM; Ancarani V; Pancisi E; Soldati V; Cassan S; Bulgarelli J; Riccobon A; Gentili G; Nanni O; Framarini M; Tauceri F; Guidoboni M
BMJ Open; 2018 Aug; 8(8):e021701. PubMed ID: 30082356
[TBL] [Abstract][Full Text] [Related]
12. Effect of CXC chemokine platelet factor 4 on differentiation and function of monocyte-derived dendritic cells.
Xia CQ; Kao KJ
Int Immunol; 2003 Aug; 15(8):1007-15. PubMed ID: 12882838
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial.
Trepiakas R; Berntsen A; Hadrup SR; Bjørn J; Geertsen PF; Straten PT; Andersen MH; Pedersen AE; Soleimani A; Lorentzen T; Johansen JS; Svane IM
Cytotherapy; 2010 Oct; 12(6):721-34. PubMed ID: 20429791
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of autologous serum on CD34(+) or monocyte-derived dendritic cells.
Loudovaris M; Hansen M; Suen Y; Lee SM; Casing P; Bender JG
J Hematother Stem Cell Res; 2001 Aug; 10(4):569-78. PubMed ID: 11522239
[TBL] [Abstract][Full Text] [Related]
15. Effective induction of melanoma-antigen-specific CD8+ T cells via Vγ9γδT cell expansion by CD56(high+) Interferon-α-induced dendritic cells.
Nieda M; Terunuma H; Eiraku Y; Deng X; Nicol AJ
Exp Dermatol; 2015 Jan; 24(1):35-41. PubMed ID: 25363560
[TBL] [Abstract][Full Text] [Related]
16. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine.
O'Rourke MG; Johnson M; Lanagan C; See J; Yang J; Bell JR; Slater GJ; Kerr BM; Crowe B; Purdie DM; Elliott SL; Ellem KA; Schmidt CW
Cancer Immunol Immunother; 2003 Jun; 52(6):387-95. PubMed ID: 12682787
[TBL] [Abstract][Full Text] [Related]
17. Efficient presentation of tumor idiotype to autologous T cells by CD83(+) dendritic cells derived from highly purified circulating CD14(+) monocytes in multiple myeloma patients.
Ratta M; Curti A; Fogli M; Pantucci M; Viscomi G; Tazzari P; Fagnoni F; Vescovini R; Sansoni P; Tura S; Lemoli RM
Exp Hematol; 2000 Aug; 28(8):931-40. PubMed ID: 10989194
[TBL] [Abstract][Full Text] [Related]
18. Monocyte derived dendritic cells have reduced expression of co-stimulatory molecules but are able to stimulate autologous T-cells in patients with MDS.
Davison GM; Novitzky N; Abdulla R
Hematol Oncol Stem Cell Ther; 2013 Jun; 6(2):49-57. PubMed ID: 23714180
[TBL] [Abstract][Full Text] [Related]
19. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses.
Wei Y; Sticca RP; Holmes LM; Burgin KE; Li J; Williamson J; Evans L; Smith SJ; Stephenson JJ; Wagner TE
Int J Oncol; 2006 Mar; 28(3):585-93. PubMed ID: 16465362
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy of malignant melanoma with tumor lysate-pulsed autologous monocyte-derived dendritic cells.
Kim DS; Kim DH; Goo B; Cho YH; Park JM; Lee TH; Kim HO; Kim HS; Lee H; Lee JD; Byamba D; Je JH; Lee MG
Yonsei Med J; 2011 Nov; 52(6):990-8. PubMed ID: 22028165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
